News

Reprieve Cardiovascular has closed an oversubscribed Series B financing round, raising $61m, for the trial of the Reprieve ...
Patient demonstrations, ongoing clinical trials and heavy investment signal that BCIs could be commercialised by 2030.
The rise of agentic artificial intelligence (AI) is liable to have multiple use cases for healthcare in patient-facing areas ...
Conformal has completed a Series D extension financing round, securing $32m to support its clinical trial of the CLAAS ...
HeartFlow’s $364m initial public offering (IPO) signals market validation for the use artificial intelligence (AI) in a ...
The SEMR JV between Interventional Systems and HICREN has obtained approval for the Intelligent SpinePecker spinal surgical ...
SetPoint Medical has secured $140m in private financing to accelerate the commercialisation of its SetPoint System, a ...
Drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity ...
Singapore-based HistoIndex has launched a new artificial intelligence (AI)-based laboratory developed test (LDT) in the US for measuring fibrosis in patients with metabolic dysfunction-associated ...
On 8 August, the US Food and Drug Administration (FDA) granted accelerated approval to Hernexeos (zongertinib) - a human epidermal growth factor receptor 2 (HER2) selective tyrosine kinase inhibitor - ...
The US Food and Drug Administration (FDA) has granted approval for Thermo Fisher Scientific’s Oncomine Dx Target Test as a treatment for non-small cell lung cancer (NSCLC). The test serves as a ...
SetPoint Medical has secured $140m through private financing, earmarked for the commercial rollout of the SetPoint System.